Your session is about to expire
← Back to Search
RNAi
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars
Phase 2
Waitlist Available
Research Sponsored by RXi Pharmaceuticals, Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing RXI-109, a treatment to reduce thick, raised scars after surgery. It targets patients who have had surgery to improve an existing scar. The treatment works by preventing the body from making too much scar tissue.
Eligible Conditions
- Hypertrophic Scar
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 9 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Reducing the recurrence of hypertrophic scar after scar revision surgery
Secondary study objectives
Safety evaluation of RXI-109
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: RXI-109Experimental Treatment1 Intervention
RXI-109 dosed at the site of the revised hypertrophic scar
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RXI-109
2012
Completed Phase 2
~80
Find a Location
Who is running the clinical trial?
RXi Pharmaceuticals, Corp.Lead Sponsor
6 Previous Clinical Trials
163 Total Patients Enrolled
Pamela Pavco, PhDStudy DirectorRXi Pharmaceuticals
3 Previous Clinical Trials
124 Total Patients Enrolled